Perindopril
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Perindopril: From Hypertension to Malignant Hypertensive Renal Disease
One-Sentence Summary
Perindopril is an angiotensin-converting enzyme inhibitor (ACEi), a drug class with well-established use in hypertension and heart failure. The TxGNN model predicts it may be effective for Malignant Hypertensive Renal Disease, with no clinical trials and 1 publication currently identified, and this is presently a mechanism-driven research hypothesis rather than an evidence-backed indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (based on known ACEi drug class; TFDA/TGA-specific approved indication text is not available in this evidence pack) |
| Predicted New Indication | Malignant Hypertensive Renal Disease |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L4 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, perindopril is an angiotensin-converting enzyme inhibitor (ACEi), its efficacy in hypertension has been proven, and mechanistically it may be applicable to malignant hypertensive renal disease through reduction of angiotensin II-mediated intraglomerular pressure and vascular tone.
Malignant hypertensive renal disease is a severe end-organ manifestation of uncontrolled hypertension, and ACEi-class agents are pharmacologically linked through their ability to lower systemic and intrarenal vascular pressure. This mechanistic overlap is why the TxGNN model scores this indication highly.
However, this same mechanism carries an important caution: in settings where renal impairment is driven by significant renal artery pathology, ACEi therapy can precipitate acute kidney injury, and bilateral renal artery stenosis is a recognised contraindication for this drug class. Any use in malignant hypertensive renal disease would need careful exclusion of renovascular involvement before initiation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36382821 | 2022 | Cohort (observational, non-drug-interventional) | Urologiia (Moscow, Russia: 1999) | Describes renal function outcomes in a solitary kidney following nephrectomy for renal cancer; does not evaluate perindopril or drug therapy directly, and its relevance to this indication has not yet been assessed |
Australia Market Information
Perindopril currently has no listed entries on the Australian Register of Therapeutic Goods (ARTG) in the data available to this evidence pack.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This indication is supported only by mechanistic reasoning — there are no clinical trials evaluating perindopril in malignant hypertensive renal disease, and the single identified publication is an observational study unrelated to drug efficacy. A blocking data gap on TFDA/TGA product information warnings and contraindications means safety cannot yet be screened.
To proceed, the following is needed:
- TGA-approved Product Information (PI): warnings, precautions and contraindications (blocking gap)
- Confirmed mechanism of action documentation for perindopril
- Prospective or retrospective studies specifically evaluating perindopril (or ACEi class) in malignant hypertensive renal disease
- Exclusion of renal artery stenosis/renovascular involvement before any use is considered, given the known ACEi class risk of acute kidney injury in that setting
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.